Who are Mescaline sodium enteric-coated tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Migranal nasal spray at 1 hour, Triptans, Sumatriptan+Promethazine (SPr), AD-227A, rizatriptan benzoate (MK0462), Usual DMT continuation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mescaline-sodium-enteric-coated-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Mescaline sodium enteric-coated tablets — Competitive Intelligence Brief

Mescaline sodium enteric-coated tablets (Mescaline sodium enteric-coated tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor agonist; psychedelic. Area: Psychiatry/Neurology (research/investigational).

marketed Serotonin receptor agonist; psychedelic 5-HT2A receptor (primary); non-selective serotonin receptors Psychiatry/Neurology (research/investigational) Small molecule Live · refreshed every 30 min

Target snapshot

Mescaline sodium enteric-coated tablets (Mescaline sodium enteric-coated tablets) — Xiangya Hospital of Central South University. Mescaline is a naturally occurring psychedelic alkaloid that acts as a non-selective serotonin receptor agonist, primarily at 5-HT2A receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mescaline sodium enteric-coated tablets TARGET	Mescaline sodium enteric-coated tablets	Xiangya Hospital of Central South University	marketed	Serotonin receptor agonist; psychedelic	5-HT2A receptor (primary); non-selective serotonin receptors
Migranal nasal spray at 1 hour	Migranal nasal spray at 1 hour	Thomas Jefferson University	marketed	Ergot alkaloid; serotonin receptor agonist	5-HT1B receptor, 5-HT1D receptor
Triptans	triptans	Pfizer	marketed	Selective serotonin receptor agonists	Serotonin 5-HT1B/1D receptors
Sumatriptan+Promethazine (SPr)	Sumatriptan+Promethazine (SPr)	Shahid Beheshti University of Medical Sciences	phase 3	Serotonin receptor agonist, Antihistamine, Anticholinergic	5-HT1B, 5-HT1D
AD-227A	AD-227A	Addpharma Inc.	phase 3	Serotonin receptor agonist	5-HT2A receptor
rizatriptan benzoate (MK0462)	rizatriptan benzoate (MK0462)	Organon and Co	phase 3	Serotonin receptor agonist	5-HT1B/1D receptor
Usual DMT continuation	Usual DMT continuation	University Hospital, Strasbourg, France	phase 3	Serotonin receptor agonist	5-HT2A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin receptor agonist; psychedelic class)

Xiangya Hospital of Central South University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mescaline sodium enteric-coated tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/mescaline-sodium-enteric-coated-tablets. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab